David Hsia is a physician with 23 years of experience. He currently practices adult critical care and pulmonology at Harbor-UCLA Medical Center.
He is a co-founder of Watson Pharmaceuticals, which is publicly traded on the New York Stock Exchange (ticker: WPI). Prior to his retirement in 2011, he served as Senior Vice President, Scientific Affairs for Watson before its listing on the NYSE.
Early Life and Education
David Hsia earned his undergraduate degree from Haverford College before going on to receive a law degree from Yale University and a doctorate from Harvard Medical School.
Though renowned for his work in health services research, he also boasts an impressive academic background and numerous professional awards. Furthermore, he has authored multiple books on various aspects of the healthcare industry.
One of his greatest accomplishments was designing a new health system for Washington, DC. Since then, he has become an expert on healthcare systems and policy matters. When not consulting, he enjoys traveling around the world and learning about different cultures. Furthermore, he founded Watson Pharmaceuticals – a small pharmaceutical company which helped boost his net worth considerably.
David Hsia has an extensive professional background in legal matters. As a seasoned attorney, he has practiced law both domestically and abroad.
He is a member of Kirkland & Ellis, LLP in both New York and London where his practice areas include corporate and securities law and private equity.
He has represented financial sponsors in private and public mergers & acquisitions, venture capital transactions, joint ventures and financings. Furthermore, he provides advice to public companies regarding securities offerings, IPOs and other strategic transactions. Furthermore, he frequently lectures and writes about private equity topics.
Achievements and Honors
David Hsia has earned numerous awards and honors for his accomplishments and contributions to medicine. As a triple board-certified doctor of internal medicine, endocrinology, and clinical lipidology he has received recognition across these fields.
He is an esteemed health services researcher and administrator, holding both a Bachelor’s degree from Haverford College as well as a Juris Doctor degree from Yale University.
His research is focused on the role of the fibronectin receptor integrin ligand FAK in tumor cell migration and morphogenesis, as well as its potential application in checkpoint immunotherapy treatments for ovarian cancer. To address important questions in cancer biology, he employs cutting-edge research tools and syngeneic mouse tumor models from ovarian syngeneic mice. Furthermore, he has trained many graduate students, postdoctoral fellows, and MD fellows who are now making contributions to oncology research fields.
David hsia is a board-certified Critical Care Medicine Specialist who practices at University Eye Care Physicians and Harbor-UCLA Medical Center in Torrance, CA.
He is a member of both the American Academy of Critical Care Medicine and Asian Pacific Association of Pulmonologists, as well as chairing its Education Committee.
Hsia was a former journalist and Chinese literary critic who traveled to the United States in 1947, during which time he became embroiled in China’s Cold War cultural politics. Afterwards, he studied English literature and European culture.
He wrote the screenplay Shanghai Calling, about an adventurous British expat running a private investigation company in bustling Shanghai. Critics praised its “fizzy, sure-footed” script. The film went on to win several awards at the Los Angeles Asian Pacific Film Festival.
Hsia, Asia’s highest-earning billionaire, owns Hutchison Whampoa Chairman David Hutchison – the world’s largest operator of container terminals. Additionally, he runs a healthcare conglomerate and the world’s largest mobile business.
Hsia is renowned for his generous giving, having donated more than $1 million to charities. His foundations support a variety of causes. Additionally, he serves as trustee of the American Cancer Society and board member at University of California at Irvine.
He is estimated to have a net worth of $325-499K. Most of his wealth comes from real estate investments, including properties in Hong Kong such as Park Lane Hotel and Causeway Bay. Furthermore, he owns shares in Noble Group – a commodities firm that supplies coal, oil and soybeans – plus he invests in renewable energy projects.